TB

In this video CDC's Dr. LoBue discussing the updated recommendations for the 12-dose treatment regimen for latent TB infection.

This information sheet  provides a comprehensive overview of tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis that primarily affects the lungs but can involve other parts of the body. It distinguishes between Latent TB Infection (LTBI), which is asymptomatic and non-infectious, and active TB disease, which can be pulmonary (infectious) or extrapulmonary (non-infectious).

Recent weeks have seen a handful of new Tuberculosis (TB) cases reported in states including Maine, North Carolina and California. While TB is rare in the U.S., even a single active case warrants attention. This article provides an overview of what TB is & how it spreads. TB is caused by a bacterium (Mycobacterium tuberculosis) that typically attacks the lungs, forming lesions called “tubercles,” and can destroy lung tissue — severe disease can lead to respiratory failure.

This article reviews key clinical and public health considerations surrounding recent tuberculosis (TB) cases reported in Maine, North Carolina, and California. Although TB remains relatively rare in the United States, it continues to cause more than 1 million deaths annually worldwide and poses ongoing risks, particularly for individuals with weakened immune systems or those who live or work in congregate settings.

This webinar session, Tuberculosis: A Disease Neglected, Misunderstood, but Deadly, provides a comprehensive overview of TB’s microbiology, pathophysiology, and current epidemiology, along with effective strategies for public health prevention and clinical management. Facilitated by Gavin Harris, MD (Emory University), the program features didactic instruction from Marcos C.

The webinar is to enhance community medical providers’ awareness of latent tuberculosis infection (LTBI). A brief overview of latent tuberculosis vs. active tuberculosis is given along with the most recent numbers of TB cases in NYS and CDC estimates of those with LTBI. It encourages community providers to assess their patients for TB risk factors, then test and treat them for LTBI as indicated.

This webinar recording discusses tests for TB and drug resistance. It also reviews TB screening, diagnosis, treatment monitoring, and more. 

This report evaluates the current needs, protocols, and promising practices for latent tuberculosis infection (LTBI) and tuberculosis (TB) screening, testing, and treatment among community health centers serving Asian American/Asian (A/AA) and Native Hawaiian/Pacific Islander (NH/PI) populations.